Lipocine inc. receives complete response letter for tlando from u.s. fda

Lipocine inc. announced that it has received a complete response letter ("crl") from the united states food and drug administration ("fda") regarding its new drug application ("nda") for tlando™, the company's oral testosterone product candidate for testosterone replacement therapy ("trt") in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. a crl is a communication from the fda that informs companies that an application cannot be approved in its present form.
LPCN Ratings Summary
LPCN Quant Ranking